SINOVAC Issues Statement Regarding Privy Council Judgment
SINOVAC’s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC’s significant value for the benefit of all shareholders.
Since the 2018 Annual General Meeting, the Company has a strong track-record of creating tremendous value for all shareholders, having implemented several innovative, life-saving, and value-creating initiatives, including SINOVAC’s leading role in combating the global COVID-19 pandemic delivering 2.9 billion doses or 22% of total global vaccination in the pandemic period.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company’s website at www.sinovac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116121834/en/
Website: http://www.sinovac.com/
Contact
Sinovac Biotech Ltd.
Helen Yang
+86-10-8279 9779
ir@sinovac.com
